Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC)
Affiliation
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UKIssue Date
2018
Metadata
Show full item recordCitation
Hall M, Bertelli G, Li L, Green C, Chan S, Yeoh CC, et al. 984P Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC). Annals of Oncology. 2018;29(suppl_8).Journal
Annals of OncologyDOI
10.1093/annonc/mdy285.191PubMed ID
No PMIDAdditional Links
https://dx.doi.org/10.1093/annonc/mdy285.191Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy285.191